Related Experiment Video
Updated: Jun 24, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Second-line therapy for non-small-cell lung cancer
Belisario A Arango1, Aurelio B Castrellon, Edgardo S Santos
1Division of Hematology and Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.
Clinical Lung Cancer
|April 14, 2009
Summary
Targeted agents offer hope for non-small-cell lung cancer (NSCLC) treatment, improving survival rates when combined with chemotherapy. This review focuses on second-line targeted therapies for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Carcinogenesis involves genomic instability, cell-cycle disruption, and aberrant signaling pathways promoting cancer growth.
- Non-small-cell lung cancer (NSCLC) treatment remains challenging despite advances, with historically poor survival rates.
- Targeted agents represent a significant advancement, offering specific pathway inhibition with improved tolerability.
Purpose of the Study:
- To review the current landscape of second-line treatments for non-small-cell lung cancer (NSCLC).
- To discuss the development and role of targeted agents in the second-line setting for NSCLC.
- To highlight the potential of targeted therapies in combination strategies for advanced lung cancer.
Main Methods:
- Literature review of studies on targeted agents in NSCLC.
- Analysis of clinical trial data for second-line NSCLC treatments.
- Synthesis of information on efficacy, safety, and development of targeted therapies.
Main Results:
- Combination regimens of chemotherapy and targeted agents show improved response rates and survival in NSCLC.
- Targeted agents demonstrate efficacy by inhibiting specific oncogenic pathways crucial for tumor progression.
- Novel targeted agents offer a favorable toxicity profile compared to traditional chemotherapy.
Conclusions:
- Targeted agents are a promising addition to the NSCLC treatment armamentarium, particularly in the second-line setting.
- Combination therapies involving targeted agents hold significant potential for improving patient outcomes in NSCLC.
- Further development and strategic application of targeted therapies are crucial for advancing lung cancer care.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...